Adaptive, collaborators to present over 30 abstracts on clonoSEQ MRD testing

Adaptive Biotechnologies together with its collaborators will present data from more than 30 abstracts demonstrating the actionability of Adaptive’s next-generation sequencing-based clonoSEQ test in assessing minimal residual disease in blood cancer patients at the 65th Annual Meeting of the American Society of Hematology, ASH, December 9-12 in San Diego, California. “Data continue to mount which reinforce the prognostic value of MRD and highlight its growing role in the blood cancer treatment landscape,” said Susan Bobulsky, Senior Vice President, Diagnostics, Adaptive Biotechnologies. “clonoSEQ provides actionable insights which are guiding the personalization of care for blood cancer patients today, as well as shaping the future of blood cancer treatment by supporting the development of cutting-edge therapeutics.” Data supporting clonoSEQ’s clinical and research utility, as well as insights based on analysis of real-world experience, will be featured in a late-breaking presentation, eight oral presentations and 24 posters across lymphoid malignancies. Studies will be presented demonstrating the clinical actionability of MRD testing across disease states. Notably, data illustrating the prognostic value of clonoSEQ MRD assessment using peripheral blood in MM and from circulating tumor DNA in DLBCL will also be presented. Additionally, biopharmaceutical companies and other investigators will share data from 13 studies using clonoSEQ as an endpoint to measure deep responses during or after therapy, including novel treatment regimens such as CAR T-cell therapies and bispecifics.